1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Sanofi-Aventis settles Allegra patent suits in US

 
• By Nancy Faigen

[C#198601345:Sanofi-Aventis]has agreed to settle some long-standing US patent infringement suits with [C#198601369:Barr Pharmaceuticals]and [C#198601169:Teva] Pharmaceutical Industriesrelated to Allegra (fexofenadine), granting the generics makers certain patent rights. As the two generics firms are already marketing US versions of the allergy drug, there will be some royalties for what has been sold in the past and royalties for future sales.

Sanofi-Aventishas agreed to settle some long-standing US patent infringement suits with Barr Pharmaceuticalsand Teva Pharmaceutical Industriesrelated to Allegra (fexofenadine), granting the generics makers certain patent rights. As the two generics firms are already marketing US versions of the allergy drug, there will be some royalties for what has been sold in the past and royalties for future sales.

The terms of the agreement pertain to generic versions of Allegra tablets 30mg, 60mg and 180mg; the agreement ends patent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

More from Therapeutic Category

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.